Clinical outcomes of long-term inhaled combination therapies in patients with bronchiectasis and airflow obstruction

Table 5 Acute exacerbation and annual FEV₁ change according to the blood eosinophil count

	Moderate-to-severe exacerbation			Annual FEV₁ change, mL/yr
	adjusted HR^a (95% CI)	P-value			Adjusted β-coefficient^b (95% CI)	P-value
Blood eosinophil count, ≥ 300/uL
ICS/LABA (compared with LABA/LAMA)	0.196 (0.045–0.861)		0.031	-137.06 (-428.66–154.53)		0.361
ICS/LABA/LAMA (compared with LABA/LAMA)	0.137 (0.034–0.553)		0.005	246.45 (-63.80–556.70)		0.128
Blood eosinophil count, 200–299/uL
ICS/LABA (compared with LABA/LAMA)	0.944 (0.175–5.101)		0.947	-42.72 (-398.09–312.65)		0.817
ICS/LABA/LAMA (compared with LABA/LAMA)	0.655 (0.098–4.388)		0.663	191.80 (-39.03–422.64)		0.123
Blood eosinophil count, < 200/uL
ICS/LABA (compared with LABA/LAMA)	1.918 (0.465–7.908)		0.368	-197.18 (-307.04–-87.32)		< 0.001
ICS/LABA/LAMA (compared with LABA/LAMA)	1.467 (0.462–4.658)		0.515	9.63 (-115.23–134.49)		0.880

Note: Data were analyzed with mixed linear regression and are presented as linear regression coefficient and standard error
^a Adjusted hazard ratio was estimated using covariables including age, current smoker, mMRC grade, baseline FEV₁, and number of exacerbations in previous year.
^b Adjusted β-coefficient was estimated using covariables including age, sex, BMI, current smoker, mMRC grade, baseline FEV₁, and previous history of moderate or severe exacerbation.

ISSN: 1471-2466